Early Prediction of Treatment Response to Atezolizumab and Bevacizumab in Advanced Liver Cancer

What this Trial Is About

This research aims to develop a model to predict early treatment response in patients with advanced hepatocellular carcinoma, a type of liver cancer with a poor prognosis compared to other cancers. The study focuses on comparing the combination therapy of atezolizumab and bevacizumab with each drug alone, as there is currently no information on how to evaluate treatment response early for this combination. The goal is to improve understanding of treatment effects in this patient group. Participants in the study are adults aged 18 to 80 years diagnosed with advanced hepatocellular carcinoma who receive atezolizumab and bevacizumab every three weeks as first-line therapy. Before the second treatment cycle, blood tests and imaging are performed around week 5 to assess early response, followed by standard response evaluations between weeks 9 and 12. This observational study tracks patients receiving standard treatment without altering therapy. During the study, researchers monitor progression-free survival and overall survival, with follow-up continuing until June 22, 2025. Participants undergo blood and imaging tests to evaluate treatment response. The study excludes patients with severe contrast allergies or significant other health problems. Participation involves regular clinical visits and tests over the follow-up period, aiming to gather data for the predictive model.

Ate-Bev Early Response Prediction Model in Advanced HCC